Spectral Medical Inc T.EDT

All Spectral Investors..

[hmmmmmmmm]

Every shareholder who is concerned with this statement from Spectral declaring they have NO responsability to disclose to investors details of the loss of control of DIMI and SAMI and the giving away of the FDA approvals that we collectively invested millions of dollars in obtaining- must take 30 seconds and speak up. Our investment looks like it may be in real jeopardy.

Send an email to the Spectral addresses below- simply cut and paste or ask the following:


1. Is the statement below Spectral's legal position on the loss of control of DIMI and SAMI?

2. If this is Spectral's official statement, Spectral must release it in the form of a PR on Sedar, and not anonomously as a post on Stockhouse, and/or selectivly only to readers of Stockhouse.

3. As investors we wholeheartedly disagree with the stated legal opinion. We believe the loss of control of DIMI and SAMI is a clear material change, and demand a Material Change Report. (NI 51-102)

"Information regarding the restructuring of Dialco in contained in our press release of December 13, 2022 (the “Dialco Restructuring”).  Having reviewed and considered this matter internally, as well as consulting with external legal counsel, Spectral  has determined that the Dialco Restructuring was not a material transaction for it - whether from an asset, income or strategic perspective or otherwise.  Nor did it constitute a material change for Spectral such that it was of the nature of a change in the business, operations or capital that would reasonably be expected to have a significant effect on the market price or value of any of the securities of Spectral. This determination was validated by the fact that there was not in fact any material change in the trading price of the Spectral common shares on the TSX in the trading days following the public announcement of the Dialco Restructuring.
 
As such, Spectral was not required to file a material change report in respect of the Dialco Restructuring, nor was Spectral required to file or publicly disclose the transaction agreements relating to the Dialco Restructuring (the “Transaction Agreements”) on SEDAR.  As such, given that Spectral is not required by law to provide additional disclosure regarding the Dialco Restructuring, the provisions of the Transaction Agreements prevent further disclosure of the confidential terms of the Transaction Agreements without the approval of Infomed, which is not forth coming.  However, some further details of the Dialco Restructuring will be contained in our annual financial statements and accompanying MD&A for the period ended December 31, 2022, which we expect to publish at the end of March 2023."

[e-mail]
 

[e-mail]
 

[e-mail]
 

[e-mail]
 

[e-mail]
 

[e-mail]

 

[e-mail]
 

[e-mail]

[e-mail]

 

 

Step 2 is coming shortly.
This move by Management is very worrying. Our investment in Spectral has gone from something we can debate about on this site to looking like a 3 alarm rug pull. The comparisons to BIOMS are scary and the same insiders are invested here.